Stiefel Laboratories, BASF, Uluru, BiPar Sciences and NanoBio - People on the move
all had people on the move in the world of pharmaceutical
manufacturing.
Stiefel Laboratories has added two new names to its board of directors, the company's COO Jeffrey Thompson and a representative of The Blackstone Group, Lodewijk de Vink. De Vink has been elected to the board following the private equity firm's $500m investment in Stiefel. Thompson is currently responsible for global operations at the company, including faciltities management, supply chain and technical operations and quality compliance among other duties. He was previously president of Stiefel subsidiary, Glades Pharmaceuticals. Chemicals specialist BASF has announced a significant reshuffle in its management team, with half a dozen changes at the top. As of January 2008, senior vice president of strategic planning Bernhard Nick will assume responsibility for Verbund Site Management Europe, becoming site manager of BASF Ludwigshafen Verbund site and succeeding Harald Schwager. At the same time, Gabriel Tanbourgi will take over the BASF fine chemicals division, replacing Wolfgang Büchele. In December, Walter Gramlich, current head of the company's intermediates division, will assume responsibility for the strategic planning and controlling division. He succeeds Rainer Strickler, who is due to retire at the end of the year. As of the beginning of November, Gramlich will be succeeded as president by Beate Ehle, current group vice president of performance chemicals for detergents and formulators, Europe. Speciality pharma firm Uluru this week announced the appointment of Renaat Van den Hoof as executive vice president of operations at the company. Van den Hoof joins Uluru from previous positions at Johnson & Johnson, McNeil International and Johnson & Johnson-Merck Consumer Pharmaceuticals. BiPar Sciences has announced a new vice president of regulatory affairs at the company, appointing Deborah Thomas to the position. Thomas joins the company after 17 years at Genentech, where she most recently held the position of senior director of clinical regulatory affairs. Before this, Thomas began her career as a toxicologist at Syntex Research. BiPar has also appointed a new vice president of corporate development, in the form of industry veteran Eric Malek. NanoBio has announced the addition of a number of players to it drug development team. Lyou-fu Ma will join the team taking on the position of senior vice president of development and regulatory affairs at the company, joining from previous positions at Pfizer and Janssen Research Technology Center. Susan Ciotti has also joined the company from Pfizer, leaving its research formulations division to take on the role of head of formulation R&D at NanoBio. Prior to her time at Pfizer, Ciotti was principal scientist at the topical formulations and drug delivery technology resource center at Johnson & Johnson. Robert Hagan has also joined the NanoBio team as senior manager of supply chain, coming from similar positions at companies including Pfizer, Pharmacia and Warner-Lambert/Parke- Davis. The final addition to the company will be Paula Robinson, bringing drug development experience from previous roles at Pfizer and Warner-Lambert/Parke-Davis to her new role as clinical project manager.
